BioSpace News Archive

Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) (the “Company” or “Inspira Technologies”), announced today that it has signed an exclusive summary distribution agreement with Glo-Med Networks Inc. (“Glo-Med”), for distribution across 6 states in the United States (Texas, New Jersey, New York, Florida, North Carlina and South Carolina).

Kite, a Gilead Company (Nasdaq: GILD), today announced the U.S. Food and Drug Administration (FDA) has approved an update to the prescribing information for Yescarta® (axicabtagene ciloleucel) to include use of prophylactic corticosteroids across all approved indications.

Covis Pharma Group, a global specialty pharmaceutical company that markets therapeutic solutions for patients with life-threatening conditions and chronic illnesses, announced the joining of Michelle Lock as Chief Operating Officer, effective February 7, 2022, and the internal appointment of Sandy Loreaux as President, U.S. Business, with immediate effect.

Fifth Eye today announced the FDA provided clearance to market its second generation clinical decision support software, the AHI System™, to hospitals in the United States.

The 2022 Orthopaedic Research and Education Foundation Clinical Research Award was presented to Martha Murray, MD, FAAOS, and her collaborators for outstanding clinical research related to musculoskeletal disease or injury.

The 2022 Kappa Delta Elizabeth Winston Lanier Award, which recognizes research in musculoskeletal disease or injury with great potential to advance patient care, was awarded to L. Scott Levin, MD, FACS, FAOA, FAAOS.

The 2022 Kappa Delta Anne Doner Vaughn Award was presented to Lawrence J. Bonassar, PhD, for his research on the microscale mechanics and composition of articular cartilage and their relevance to musculoskeletal disease.

Scitara, proven innovator in laboratory digital transformation, announces it has become a member of BioPhorum, a global community that enables collaboration throughout the biopharmaceutical industry with the goal of accelerating scientific advancements.

Today, the U.S. Food and Drug Administration approved a second COVID-19 vaccine. The vaccine has been known as the Moderna COVID-19 Vaccine; the approved vaccine will be marketed as Spikevax for the prevention of COVID-19 in individuals 18 years of age and older.

Novavax, Inc. today announced that it has submitted a request to the U.S Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) for NVX-CoV2373.